Overview

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

Status:
Completed

Trial end date:
2020-04-07

Target enrollment:

Participant gender:

Summary

The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer